← back to search

Ulf P. Neumann

Friedrich-Alexander-Universität Erlangen-Nürnberg · DE
Area of research
Surgery · Hepatology
Research interest
Research interests include Organ Transplantation Techniques and Outcomes, Hepatocellular Carcinoma Treatment and Prognosis, Cholangiocarcinoma and Gallbladder Cancer Studies, and Liver Disease and Transplantation.
h-index
70
citations
20,118
works
789
NIH funding
primary concept
Medicine
email

Recent publications

Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial).
Journal of Clinical Oncology 2024cited by 91position: middledoi
Higher Postoperative Mortality and Inferior Survival After Right-Sided Liver Resection for Perihilar Cholangiocarcinoma: Left-Sided Resection is Preferred When Possible
Annals of Surgical Oncology 2024cited by 31position: middledoi
S2k-Leitlinie Lebertransplantation der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV)
Zeitschrift für Gastroenterologie 2024cited by 24position: middledoi
Failure to Rescue After Resection of Perhilar Cholangiocarcinoma in an International Multicenter Cohort
Annals of Surgical Oncology 2024cited by 10position: middledoi
Regulation of KIF23 by miR-107 controls replicative tumor cell fitness in mouse and human hepatocellular carcinoma
Journal of Hepatology 2024cited by 6position: middledoi
Body Composition in Cholangiocarcinoma Affects Immune Cell Populations in the Tumor and Normal Liver Parenchyma
Journal of Clinical and Experimental Hepatology 2024cited by 1position: middledoi
Sublethal necroptosis signaling promotes inflammation and liver cancer
Immunity 2023cited by 131position: middledoi
Predicting futility of upfront surgery in perihilar cholangiocarcinoma: Machine learning analytics model to optimize treatment allocation
Hepatology 2023cited by 35position: middledoi
Intersurgeon Variability in Local Treatment Planning for Patients with Initially Unresectable Colorectal Cancer Liver Metastases: Analysis of the Liver Expert Panel of the Dutch Colorectal Cancer Group
Annals of Surgical Oncology 2023cited by 17position: middledoi
The role of tumour biological factors in technical anatomical resectability assessment of colorectal liver metastases following induction systemic treatment: An analysis of the Dutch CAIRO5 trial
European Journal of Cancer 2023cited by 14position: middledoi
Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy
Annals of Surgical Oncology 2023cited by 12position: middledoi
Hepatocellular loss of mTOR aggravates tumor burden in nonalcoholic steatohepatitis-related HCC
Neoplasia 2023cited by 7position: middledoi
Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial.
Journal of Clinical Oncology 2022cited by 114position: middledoi
Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic
Journal of Cancer Research and Clinical Oncology 2022cited by 21position: middledoi
Feasibility and Efficacy of Adjuvant Chemotherapy With Gemcitabine After Liver Transplantation for Perihilar Cholangiocarcinoma - A Multi-Center, Randomized, Controlled Trial (pro-duct001)
Frontiers in Oncology 2022cited by 14position: middledoi
Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines
Annals of Oncology 2021cited by 453position: middledoi
Hypothermic Oxygenated Machine Perfusion Reduces Early Allograft Injury and Improves Post-transplant Outcomes in Extended Criteria Donation Liver Transplantation From Donation After Brain Death
Annals of Surgery 2021cited by 244position: middledoi
Perihilar Cholangiocarcinoma – Novel Benchmark Values for Surgical and Oncological Outcomes From 24 Expert Centers
Annals of Surgery 2021cited by 170position: middledoi
The rate of cholangiocarcinoma in Caroli Disease A German multicenter study
HPB 2021cited by 23position: middledoi
ALPPS for Locally Advanced Intrahepatic Cholangiocarcinoma: Did Aggressive Surgery Lead to the Oncological Benefit? An International Multi-center Study
Annals of Surgical Oncology 2020cited by 80position: middledoi
Consensus on definition and severity grading of lymphatic complications after kidney transplantation
British journal of surgery 2020cited by 28position: middledoi
Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306
Annals of Surgical Oncology 2020cited by 23position: middledoi
Prolonged Survival of a Patient with Advanced-Stage Combined Hepatocellular-Cholangiocarcinoma
Case Reports in Gastroenterology 2020cited by 8position: middledoi
Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer
Nature Medicine 2019cited by 1,398position: middledoi
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology 2018cited by 1,059position: middledoi
S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV) -Infektion“
Zeitschrift für Gastroenterologie 2018cited by 78position: middledoi
Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer—central evaluation of FIRE-3
European Journal of Cancer 2017cited by 88position: lastdoi
Central evaluation for surgical treatment options in FIRE-3- updated results and impact on overall Survival
Annals of Oncology 2017cited by 4position: middledoi
The necroptosis-inducing kinase RIPK3 dampens adipose tissue inflammation and glucose intolerance
Nature Communications 2016cited by 102position: middledoi
IκB kinaseα/β control biliary homeostasis and hepatocarcinogenesis in mice by phosphorylating the cell‐death mediator receptor‐interacting protein kinase 1
Hepatology 2016cited by 61position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Tom Luedde · Heinrich Heine University Düsseldorf5 papers (2016–2024)Johann Pratschke · Johnson & Johnson (United States)4 papers (2017–2021)Christian Trautwein · FH Aachen4 papers (2016–2021)Gunnar Folprecht · Helmholtz-Zentrum Dresden-Rossendorf4 papers (2017–2024)Christiane J. Bruns · Klinik und Poliklinik für Psychosomatik und Psychotherapie4 papers (2017–2024)Frank Tacke · Charité University Medicine Berlin4 papers (2016–2021)Christoph Roderburg · Charité - Universitätsmedizin Berlin3 papers (2016–2024)Thomas Becker · University Hospital Schleswig-Holstein3 papers (2017–2020)Markus Rentsch · Ludwig-Maximilians-Universität München3 papers (2017–2020)Daniel Seehofer · Comprehensive Cancer Center Mainfranken3 papers (2017–2020)Volker Heinemann · LMU Klinikum3 papers (2017–2020)Hauke Lang · Johannes Gutenberg University Mainz3 papers (2017–2020)Dominik Paul Modest · Berliner Hochschule für Technik3 papers (2017–2020) · 3 papers (2017–2020)Bernhard Gebauer · Humboldt-Universität zu Berlin3 papers (2017–2020) · 3 papers (2017–2020)Timm Denecke · University Hospital Leipzig3 papers (2017–2020)Arndt Vogel · Federal Institute for Risk Assessment3 papers (2014–2021)Peter Schirmacher · Kliniken Essen-Mitte3 papers (2018–2021)Bruno Sangro · KU Leuven2 papers (2018–2021)